Compare GFF & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFF | CELC |
|---|---|---|
| Founded | 1959 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.1B |
| IPO Year | 1994 | 2017 |
| Metric | GFF | CELC |
|---|---|---|
| Price | $67.96 | $103.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $101.50 | ★ $106.63 |
| AVG Volume (30 Days) | 275.9K | ★ 537.3K |
| Earning Date | 05-07-2026 | 03-25-2026 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $2,519,926,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $49.46 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $63.92 | $7.58 |
| 52 Week High | $97.58 | $120.32 |
| Indicator | GFF | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 24.38 | 40.10 |
| Support Level | $66.36 | $103.65 |
| Resistance Level | $78.07 | $117.27 |
| Average True Range (ATR) | 2.27 | 5.60 |
| MACD | -0.98 | -0.71 |
| Stochastic Oscillator | 3.22 | 6.20 |
Griffon Corp manufactures and markets residential, commercial and industrial garage doors to professional installing dealers and home center retail chains. It also provides non-powered landscaping products for homeowners and professionals. Its operating segments include Consumer and Professional Products: is a provider of branded consumer and professional tools; residential, industrial and commercial fans; home storage and organization products; and Home and Building Products conducts its operations through Clopay Corporation (Clopay). Clopay is the manufacturer and marketer of garage doors and rolling steel doors in North America. The company generates a majority of its revenue from the Home and Building Products segment. Operates in USA, Europe, Canada, Australia, and Others.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.